WH-4-023 is primarily utilized in biochemical research as a potent and selective inhibitor of the Bcr-Abl tyrosine kinase, particularly targeting the T315I mutant form. This mutant is associated with resistance to many existing therapies in chronic myeloid leukemia (CML). Researchers employ WH-4-023 to study the mechanisms of drug resistance and to explore potential therapeutic strategies for overcoming resistance in CML and other cancers driven by similar mutations. Its application extends to preclinical studies where it serves as a valuable tool for evaluating the efficacy of kinase inhibitors in cellular and animal models, aiding in the development of targeted cancer treatments.